GSK is handing over $300 million in upfront cash for a clinical-stage T-cell engager it believes could target patients who aren’t benefiting from current treatments. The candidate in question is CMG1A46, a dual CD19- and CD20-targeted T cell engager that Chimagen Biosciences is currently evaluating in phase 1 trials for leukemia and lymphoma. However, GSK has spied potential in focusing the asset on systemic lupus erythematosus (SLE) and lupus nephritis. Source: Fierce Biotech 29/10/2024